All Stories

Bioxodes halts phase 2 stroke trial after successful interim review, plots registrational study

Bioxodes has stopped enrolling people in a phase 2a stroke study after hitting the safety and efficacy endpoints, positioning the Belgian biotech to power into a potentially registrational trial.

Apr 24, 2025 - 14:51
 0
Bioxodes halts phase 2 stroke trial after successful interim review, plots registrational study
Bioxodes has stopped enrolling people in a phase 2a stroke study after hitting the safety and efficacy endpoints, positioning the Belgian biotech to power into a potentially registrational trial.
Read More

Tags:

Previous Article

The Fresh Market expands in Florida, Connecticut

Next Article

US interior agency to fast track permits for fossil fuel and mining projects

Related Posts

Trump HHS reevaluating Biden administration’s $590M bird flu vaccine contract with Moderna: Bloomberg

Trump HHS reevaluating Biden administration’s $590M bir...

Feb 28, 2025  0

Boehringer boards B-cell depletion bandwagon, paying Cue $12M to line up autoimmune attack

Boehringer boards B-cell depletion bandwagon, paying Cu...

Apr 15, 2025  0

Tempus AI in line for $200M from AstraZeneca, Pathos deal to develop cancer model

Tempus AI in line for $200M from AstraZeneca, Pathos de...

Apr 23, 2025  0